Causes and consequences of adynamic bone disease

Nephron

Volumn 88, Issue 2, 2001, Pages 97-106

  Heaf, James ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ERYTHROPOIETIN; GROWTH HORMONE; MAGNESIUM; PARATHYROID HORMONE; SOMATOMEDIN C; VITAMIN D;

BONE DISEASE; HUMAN; HYPOGONADISM; METABOLIC ACIDOSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN CALORIE MALNUTRITION; REVIEW; RISK FACTOR;

ANIMALS; BONE DISEASES; HUMANS; IATROGENIC DISEASE; NUTRITION DISORDERS; UREMIA;

EID: 0034955994     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045968     Document Type: Review

References (147)

1. Aluminium-associated bone disease in chronic renal failure. High prevalence in a long-term dialysis population
2. Aluminium-related bone disease in mild and advanced renal failure. Evidence for high prevalence and morbidity and studies on etiology and diagnosis
3. Histomorphometric evidence of deleterious effect of aluminium on osteoblasts
4. Noninvasive diagnosis of uremic osteodystrophy: Uses and limitations
5. Risk factors for renal osteodystrophy: A multivariant analysis
6. The spectrum of bone disease in end-stage renal failure - An evolving disorder
7. 3 intake: Emergence of an idiopathic adynamic bone disease not related to aluminium
8. Non-aluminic adynamic bone disease in non-dialyzed uremic patients: A new type of osteopathy due to overtreatment?
9. Aplastic osteodystrophy: Follow-up after 5 years
10. Aplastic osteodystrophy without aluminium: The role of 'suppressed' parathyroid function
11. Adynamic bone disease with negative aluminium staining in predialysis patients: Prevalence and evolution after maintenance dialysis
12. Histological radiological, biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients
13. Calcific uremic arteriolopathy in association with low turnover uremic bone disease
14. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease
15. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients. A national study
16. A clinical approach to the uraemic patient with extraskeletal calcifications
17. Myocardial calcification and cardiac dysfunction in chronic renal failure
18. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis
19. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients
20. Evaluation of bone mineral density in CAPD patients with dual energy X-ray absorptionometry
21. 3, and radiology in end-stage renal disease
22. The use of bone mineral content in the evaluation of osteodystrophy among haemodialysis patients
23. Bone mineral content in patients on prolonged maintenance dialysis
24. Risk factors for vertebral fractures in renal osteodystrophy
25. Risk factors for reduced bone density in hemodialysis patients
26. The identification of bone mineral density in CAPD in comparison with HD patients
27. Total and regional bone mineral density by dual photon absorptiometry in patients on maintenance hemodialysis
28. Total and regional bone densities in dialysis patients
29. Bone mass status in different degree of chronic renal failure
30. Longitudinal study of bone mass in end-stage renal disease patients: Effects of parathyroidectomy for renal osteodystrophy
31. The role of DEXA bone densitometry in evaluating renal osteodystrophy in continuous ambulatory peritoneal dialysis patients
32. Fractures and vertebral bone mineral density in patients with renal osteodystrophy
33. Long-term outcome following total parathyroidectomy in patients with end-stage renal disease
34. Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia
35. Low serum levels of alkaline phosphatase of bone origins: A good marker of adynamic bone disease in haemodialysis patients
36. Bone markers in the diagnosis of low bone turnover osteodystrophy in hemodialysis patients
37. Plasma biochemical markers of bone remodeling in patients with renal insufficiency
38. Biochemical markers for noninvasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis
39. Assessment of renal osteodystrophy in dialysis patients: Use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology
40. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples
41. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance in the interpretation of PTH values
42. Risk of adynamic bone disease in dialysed patients
43. Bone disease in predialysis, hemodialysis, and CAPD patients. Evidence for a better bone response to PTH
44. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients
45. Low calcium (1.25 mmol/l) dialysate can normalize relative hypoparathyroidism in CAPD patients with low bone turnover
46. Calcium-regulated parathyroid hormone secretion in adynamic renal osteodystrophy
47. Reversibility of parathyroid gland suppression in CAPD patients with low i-PTH levels
48. Are there any differences in the parathyroid response in the different types of renal osteodystrophy?
49. Intermittent calcitriol therapy in secondary hyperparathyroidsim: A comparison between oral and intraperitoneal administration
50. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy
51. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD
52. Is there a link between erythropoietin therapy and adynamic bone disease?
53. Lack of influence of recombinant erythropoietin on parathyroid function in hemodialysis patients with secondary hyperparathyroidism
54. Serum magnesium concentration and PTH levels. Is long-term chronic hypermagnesemia a risk factor for adynamic bone disease?
55. Relationship between serum magnesium and parathyroid hormone levels in hemodialysis patients
56. Hypermagnesemia in CAPD. Relationship with parathyroid hormone levels
57. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients
58. The influence of magnesium and calcium on parathyroid hormone secretion in man
59. Extracellular calcium sensing, regulation of parathyroid cell function, and role of calcium and other ions as extracellular (first) messengers
60. Parathyroid hormone secretion in vitro: Regulation by calcium and magnesium ions
61. Comparison of the feed-back effect of magnesium and calcium on parathyroid hormone secretion in man
62. Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: Improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations
63. Alkalosis and hypomagnesaemia: Unwanted effects of a low-calcium CAPD solution
64. Parathyroid hormone during maintenance dialysis: Influence of low calcium dialysate, plasma albumin and age
65. Hyperparathyroidism in the hemodialysis population: A survey of 612 patients
66. Insulin-like growth factor 1 and 2 serum concentrations in dialysis patients with secondary hyperparathyroidism and adynamic disease
67. Effects of high concentrations of glucose on PTH secretion in parathyroid cells
68. Is there a lesser hyperparathyroidism in diabetic patients with chronic renal failure?
69. The influence of hyperinsulinaemia on calcium-phosphate metabolism in renal failure
70. Prevention of renal osteodystrophy in peritoneal dialysis
71. Minerals, vitamin D, and parathyroid hormone in continuous ambulatory peritoneal dialysis
72. Transperitoneal removal of osteocalcin, calcitonin and parathyroid hormone in patients treated by CAPD
73. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure
74. Long-term dialysis with low-calcium solution (1.0 mmol/l) in CAPD: Effects on bone mineral metabolism
75. A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients
76. Reduced calcium dialysate in CAPD patients: Efficacy and limitations
77. Differences in calcium kinetic pattern between CAPD and HD patients
78. Adynamic bone disease with negative aluminium staining in predialysis patients: Prevalence and evolution after maintenance dialysis
79. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population
80. Adynamic bone lesion in renal transplant recipients with normal renal function
81. Bone disease in children and adolescents undergoing successful renal transplantation
82. Magnesium and calcium mass transfer during continuous ambulatory peritoneal dialysis
83. Bone remodeling alterations in myelodysplastic syndrome
84. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study
85. Calcium kinetic studies in patients on CAPD: Improvement of secondary hyperparathyroidism without concomitant improvement of calcium turnover
86. Effect of CAPD and hemodialysis on parathyroid function
87. Effect of alfacalciol on natural course of renal bone disease in mild to moderate renal failure
88. Does hypophosphatemia induce hypoparathyroidism in pre-dialysis patients?
89. 3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function
90. α-hydroxycalciferol treatment on bone mineral density in hemodialysis patients
91. Continuous ambulatory peritoneal dialysis and bone
92. Long-term follow-up after total parathyroidectomy without parathyroid reimplantation in chronic renal failure
93. Effects of excess PTH on nonclassical target organs
94. Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients
95. Calcium set point progressively worsens in hemodialysis patients despite conventional oral 1α-hydroxycholecalciferol supplementation
96. Vitamin D receptor gene polymorphisms affect secondary hyperparathyroidism in hemodialysed patients
97. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells
98. Adynamic bone disease - Is it actually a disease?
99. Rat serum osteocalcin concentration is decreased by restriction of energy intake
100. Biochemical indicators of bone formation in foals after transfer from pasture to stables for the winter months
101. Régulation nutritionelle de l'ostéocalcine serique: Étude dans le kwashiorkor
102. Growth pattern and dietary intake of children with chronic renal insufficiecy
103. Dietary protein and growth in infants with chronic renal insufficiency: A report from the Southwest Pediatric Study Group and the University of California, San Francisco
104. Relation of caloric deficiency to growth failure in children on hemodialysis and the growth response to caloric supplementation
105. Effects of calorie supplementation on growth of children with uremia
106. Growth in children with chronic renal failure on conservative treatment
107. Tetracycline double-labeling of iliac trabecular bone in 41 normal adults
108. Does hypophosphatemia induce hypoparathyroidism in pre-dialysis patients?
109. Evidence for a direct effect of growth hormone on osteoblasts
110. 3 and activity on human osteoblast-like cells in short-term cultures
111. IGF-1 production by mouse osteoblasts
112. Effects of short-term administration of rhGH to elderly people
113. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH
114. Growth hormone levels in severe renal failure
115. Abnormalities in the regulation of growth hormone in chronic renal failure
116. Plasma growth hormone-binding activity is low in uraemic children
117. Changes in bone histomorphometry during treatment with recombinant human growth hormone in children with dialysis
118. Vitamin D metabolic requirements in dialysed children receiving recombinant human growth hormone
119. Stimulation of growth by recombinant human growth hormone in children undergoing peritoneal or hemodialysis treatment
120. IGFs: Function and clinical importance. 2. The regulation of osteoblast function by hormones and cytokines with special reference to insulin-like growth factors and their binding proteins
121. Effects of rh-IGF-1 administration on bone turnover during short-term fasting
122. Insulin-like growth factor binding proteins in bone cell regulation
123. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy
124. Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre- and postmenopausal women: Relationship to age, menopause, bone turnover, and circulating IGFs
125. Plasma insulin-like growth factors and bone formation in uremic hyperparathyroidism
126. Plasma insulin-like growth factor-1 and bone formation parameters in predialysis chronic renal failure
127. Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma
128. Disturbance of growth hormone - Insulin-like growth factor axis inuremia
129. Recombinant human insulin-like growth factor binding protein-5 stimulates bone formation parameters in vitro and in vivo
130. Endocrine function adaptation in undernutrition. Aspects of some vitamins, minerals and enzymes
131. The 24/25-kDa serum insulin-like growth factor-binding proteins is increased in elderly women with hip and spine factors
132. Enhanced osteoblast proliferation and collagen expression by estradiol
133. Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-1, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones
134. Bone morphogenic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen
135. New concepts in renal osteodystrophy
136. Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: Effect of calcitriol treatment
137. Optimal correction of acidosis changes progression of dialysis osteodystrophy
138. Osteomalacia and chronic renal failure
139. Osteomalacia in patients with chronic renal failure before dialysis or transplantation
140. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis
141. A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in haemodialysed patients
142. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity
143. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia
144. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD
145. Effect of CAPD and hemodialysis on parathyroid function
146. Comparison of intact, mid-region, and carboxy-terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialysis patients